AutoBrief LogoAutoBrief
Back to news

White House Denies Trump Access to Experimental Eli Lilly Obesity Drug

The Hill1 min read55 words
Share:

White House officials on Tuesday shot down a report speculating that President Trump gained access to the retatrutide weight-loss drug under the Food and Drug Administration’s (FDA) “compassionate use program.” The retatrutide drug is manufactured by Eli Lilly and is not FDA approved, however, one person gained access to the prescription through a program that…

🤖 AI-generated content — This article was automatically summarised from public RSS feeds by AutoBrief. Verify important information with the original source.